MY182861A - Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination - Google Patents

Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination

Info

Publication number
MY182861A
MY182861A MYPI2016001207A MYPI2016001207A MY182861A MY 182861 A MY182861 A MY 182861A MY PI2016001207 A MYPI2016001207 A MY PI2016001207A MY PI2016001207 A MYPI2016001207 A MY PI2016001207A MY 182861 A MY182861 A MY 182861A
Authority
MY
Malaysia
Prior art keywords
solution composition
glycopyrronium bromide
aerosol solution
hydroxy
salt
Prior art date
Application number
MYPI2016001207A
Inventor
Sauro Bonelli
Diego Copelli
Alberi Massimiliano Dagli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49886777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY182861(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MY182861A publication Critical patent/MY182861A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/007—Mechanical counters
    • A61M15/0071—Mechanical counters having a display or indicator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A61M2039/226—Spindles or actuating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns an aerosol solution composition intended for use with a pressurised metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredient, stabilised by a selected amount of a mineral acid and wherein the amount of the degradation product N-(3-bromo)-[2-hydroxy-5-[1-hydroxy-2-[1-(4- methoxyphenyl) propan-2-ylamino]ethyl] phenyl]formamide is lower than the limit of quantification, when stored in accelerated conditions at 25?C and 60% relative humidity (RH) for 6 months in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer. The optional one or more active ingredient may be an inhalation corticosteroid selected from beclometasone dipropionate, budesonide or its 22R-epimer, ciclesonide, flunisolide, tluticasone propionate, fluticasone furoate, mometasone furoate, etc.
MYPI2016001207A 2013-12-30 2014-12-23 Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination MY182861A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199784 2013-12-30
PCT/EP2014/079259 WO2015101576A1 (en) 2013-12-30 2014-12-23 Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination

Publications (1)

Publication Number Publication Date
MY182861A true MY182861A (en) 2021-02-05

Family

ID=49886777

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016001207A MY182861A (en) 2013-12-30 2014-12-23 Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination

Country Status (34)

Country Link
US (2) US10596113B2 (en)
EP (3) EP3384898A1 (en)
JP (2) JP6563950B2 (en)
KR (2) KR101861119B1 (en)
CN (2) CN111150728B (en)
AR (1) AR098982A1 (en)
AU (1) AU2014375301B2 (en)
BR (1) BR112016014583B1 (en)
CA (1) CA2935305C (en)
CL (1) CL2016001653A1 (en)
CY (1) CY1120668T1 (en)
DK (1) DK3089735T3 (en)
EA (1) EA033227B1 (en)
ES (1) ES2687345T3 (en)
HK (1) HK1225313A1 (en)
HR (1) HRP20181551T1 (en)
HU (1) HUE039513T2 (en)
IL (1) IL246498B (en)
LT (1) LT3089735T (en)
MA (1) MA39155A1 (en)
MX (1) MX368835B (en)
MY (1) MY182861A (en)
PE (1) PE20160997A1 (en)
PH (1) PH12016501268B1 (en)
PL (1) PL3089735T3 (en)
PT (1) PT3089735T (en)
RS (1) RS57687B1 (en)
SA (1) SA516371427B1 (en)
SG (1) SG11201605311UA (en)
SI (1) SI3089735T1 (en)
TN (1) TN2016000261A1 (en)
TW (1) TWI660747B (en)
UA (1) UA117845C2 (en)
WO (1) WO2015101576A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2515854T3 (en) 2009-12-23 2014-05-26 Chiesi Farma Spa Aerosol formulation for COPD
DK2515855T6 (en) * 2009-12-23 2023-06-06 Chiesi Farm Spa Combination therapy for COPD
KR101738712B1 (en) * 2009-12-23 2017-05-22 키에시 파르마슈티시 엣스. 피. 에이. Combination therapy for copd
ES2666905T4 (en) 2013-12-30 2018-06-07 Chiesi Farmaceutici S.P.A. Composition in solution for pressurized stable aerosol of a combination of glycopyrronium bromide and formoterol
TN2016000261A1 (en) * 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
BR112018011266B1 (en) 2015-12-04 2023-11-21 Mexichem Fluor S.A. De C.V. Pharmaceutical composition, sealed container, and, methods for treating a patient suffering from or prone to suffering from a respiratory disorder and for stabilizing a pharmaceutical composition
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
ES2957459T3 (en) * 2016-09-19 2024-01-19 Mexichem Fluor Sa De Cv Pharmaceutical composition comprising glycopyrrolate
CN107233311B (en) * 2017-06-27 2020-12-04 长风药业股份有限公司 Atomizing agent with arformoterol and glycopyrronium bromide as active ingredients and preparation method thereof
WO2020084549A1 (en) * 2018-10-25 2020-04-30 Glenmark Specialty S.A. Nebulization composition comprising glycopyrrolate and formoterol
US20220241524A1 (en) * 2019-07-12 2022-08-04 Kindeva Drug Delivery L.P. Aerosol formulation, canister, and inhaler containing the formulation, and method of use
US20220395454A1 (en) 2019-12-02 2022-12-15 Chiesi Farmaceutici S.P.A. Stainless steel can for pressurised metered dose inhalers
IL294804A (en) 2020-01-28 2022-09-01 Chiesi Farm Spa Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
WO2021165348A1 (en) * 2020-02-20 2021-08-26 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
CN115989032A (en) 2020-07-31 2023-04-18 化学研究有限公司 Combination therapy for inhalation administration
CN112051346A (en) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 HPLC method for simultaneously determining content of indacaterol and glycopyrronium bromide
US20230277451A1 (en) 2020-10-09 2023-09-07 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023117985A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023227783A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227782A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227781A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
WO2000007567A1 (en) 1998-08-04 2000-02-17 Jago Research Ag Medicinal aerosol formulations
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (en) 2000-01-07 2003-07-15 Chiesi Farma Spa DEVICE FOR THE ADMINISTRATION OF AEROSOL DOSED PRESSURIZED INPROPELLENT HYDROFLUOROALKANS.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
CZ303833B6 (en) 2000-05-22 2013-05-22 Chiesi Farmaceutici S.P.A. Aerosol composition
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
EP1241113A1 (en) * 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
SI1718336T1 (en) 2004-02-06 2008-10-31 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
JP4819699B2 (en) 2004-02-06 2011-11-24 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト Anticholinergic and glucocorticoid combination for long-term treatment of asthma and COPD
UA88894C2 (en) * 2004-02-27 2009-12-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Stable pharmaceutical solution formulation for pressurized metered dose inhalers
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
CA2565747A1 (en) * 2004-05-13 2005-12-01 Chiesi Farmaceutici S.P.A. Medicinal aerosol formulation products with improved chemical stability
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006105401A2 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP2201934A1 (en) * 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
US20110132355A1 (en) * 2009-06-09 2011-06-09 William Gerhart Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
KR20120106753A (en) 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Aerosol formulation for copd
DK2515855T6 (en) * 2009-12-23 2023-06-06 Chiesi Farm Spa Combination therapy for COPD
KR101738712B1 (en) 2009-12-23 2017-05-22 키에시 파르마슈티시 엣스. 피. 에이. Combination therapy for copd
DK2515854T3 (en) 2009-12-23 2014-05-26 Chiesi Farma Spa Aerosol formulation for COPD
KR101857834B1 (en) 2010-09-06 2018-05-14 키에시 파르마슈티시 엣스. 피. 에이. Metered-dose inhaler actuator, metered-dose inhaler
SG194896A1 (en) * 2011-05-17 2013-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
WO2014033057A1 (en) 2012-08-29 2014-03-06 Chiesi Farmaceutici S.P.A. Aerosol inhalation device
TN2016000261A1 (en) * 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
ES2666905T4 (en) * 2013-12-30 2018-06-07 Chiesi Farmaceutici S.P.A. Composition in solution for pressurized stable aerosol of a combination of glycopyrronium bromide and formoterol

Also Published As

Publication number Publication date
JP2017507169A (en) 2017-03-16
US10617638B2 (en) 2020-04-14
CY1120668T1 (en) 2019-12-11
PH12016501268A1 (en) 2016-08-15
PL3089735T3 (en) 2018-12-31
KR101861119B1 (en) 2018-05-28
MX368835B (en) 2019-10-18
IL246498A0 (en) 2016-08-31
SI3089735T1 (en) 2018-10-30
NZ721642A (en) 2021-02-26
EA201691126A1 (en) 2016-12-30
HRP20181551T1 (en) 2018-11-30
WO2015101576A1 (en) 2015-07-09
US10596113B2 (en) 2020-03-24
ES2687345T3 (en) 2018-10-24
KR20160104041A (en) 2016-09-02
SA516371427B1 (en) 2018-12-24
HUE039513T2 (en) 2019-01-28
CL2016001653A1 (en) 2017-08-25
US20150182450A1 (en) 2015-07-02
MA39155A1 (en) 2017-04-28
AR098982A1 (en) 2016-06-22
JP6823118B2 (en) 2021-01-27
UA117845C2 (en) 2018-10-10
TN2016000261A1 (en) 2017-10-06
EA033227B1 (en) 2019-09-30
AU2014375301A1 (en) 2016-07-14
PH12016501268B1 (en) 2016-08-15
KR101861117B1 (en) 2018-05-28
SG11201605311UA (en) 2016-07-28
RS57687B1 (en) 2018-11-30
CN111150728B (en) 2024-02-06
PE20160997A1 (en) 2016-10-14
EP3384898A1 (en) 2018-10-10
BR112016014583B1 (en) 2022-12-20
EP3089735A1 (en) 2016-11-09
US20160303045A1 (en) 2016-10-20
DK3089735T3 (en) 2018-09-17
CN105848641A (en) 2016-08-10
TWI660747B (en) 2019-06-01
MX2016008594A (en) 2016-09-26
CA2935305C (en) 2022-07-12
KR20180032660A (en) 2018-03-30
EP3566694A1 (en) 2019-11-13
HK1225313A1 (en) 2017-09-08
TW201609185A (en) 2016-03-16
CN111150728A (en) 2020-05-15
LT3089735T (en) 2018-09-10
AU2014375301B2 (en) 2020-03-26
BR112016014583A2 (en) 2017-08-08
CN105848641B (en) 2021-07-09
CA2935305A1 (en) 2015-07-09
PT3089735T (en) 2018-10-19
JP2019206557A (en) 2019-12-05
IL246498B (en) 2020-05-31
EP3089735B1 (en) 2018-07-11
JP6563950B2 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
PH12016501268A1 (en) Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
PH12016501269A1 (en) Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
AR081540A1 (en) PROCESS TO PROVIDE PARTICLES WITH REDUCED ELECTRO-STATIC CHARGES
BR112022014228A2 (en) CALIBRATED DOSE PRESSURIZED INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION
RU2012142295A (en) METHOD FOR PREPARING CARRIER PARTICLES FOR DRY POWDERS FOR INHALATION
TW201129359A (en) Pharmaceutical composition for the treatment of COPD
NZ600789A (en) Aerosol formulation for copd
JP2014527056A5 (en)
JO3024B1 (en) Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
CO2022012207A2 (en) Pressurized metered dose inhalers comprising a buffered pharmaceutical formulation
TH171992A (en) The stable pressure-type aerosol solution composition of the combination of Glycopyronium bromide And FORMOTHERAL
TH171993A (en) The stable pressure-type aerosol solution composition of the combination of Glycopyronium bromide And FORMOTHERAL
ZA202108150B (en) An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate
RU2021104054A (en) COMPRESSED AIR MEDITED DOSE INHALATOR CONTAINING A BUFFERED PHARMACEUTICAL COMPOSITION
PL432374A1 (en) New inhalation therapeutic system delivering a reduced amount of fluticasone propionate and salmeterol with increased efficacy and safety profile
RU2021101525A (en) COMPRESSED AIR MEDITED DOSE INHALATOR CONTAINING A BUFFERED PHARMACEUTICAL COMPOSITION
TH171992B (en) The stable pressure-type aerosol solution composition of the combination of Glycopyronium bromide And FORMOTHERAL